MIM
ATRA icon

MetLife Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

MetLife Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,989
Closed -$73.6K – 2828
2023
Q3 		$73.6K Hold
1,989
– – ﹤0.01% 2738
2023
Q2 		$80.1K Hold
1,989
– – ﹤0.01% 2805
2023
Q1 		$144K Buy
1,989
+546
+38% +$53K ﹤0.01% 2395
2022
Q4 		$118K Sell
1,443
-449
-24% -$46.8K ﹤0.01% 2517
2022
Q3 		$179K Buy
1,892
+208
+12% +$23.4K ﹤0.01% 2367
2022
Q2 		$328K Sell
1,684
-183
-10% -$29.9K ﹤0.01% 1957
2022
Q1 		$434K Buy
1,867
+677
+57% +$216K ﹤0.01% 1856
2021
Q4 		$469K Hold
1,190
– – ﹤0.01% 1542
2021
Q3 		$533K Hold
1,190
– – ﹤0.01% 1485
2021
Q2 		$463K Hold
1,190
– – ﹤0.01% 1613
2021
Q1 		$427K Hold
1,190
– – ﹤0.01% 1623
2020
Q4 		$584K Hold
1,190
– – 0.01% 1410
2020
Q3 		$386K Hold
1,190
– – ﹤0.01% 1506
2020
Q2 		$434K Buy
1,190
+239
+25% +$60.4K ﹤0.01% 1461
2020
Q1 		$202K Hold
951
– – ﹤0.01% 1692
2019
Q4 		$392K Hold
951
– – ﹤0.01% 1596
2019
Q3 		$336K Buy
951
+198
+26% +$73.9K ﹤0.01% 1633
2019
Q2 		$379K Hold
753
– – ﹤0.01% 1647
2019
Q1 		$749K Hold
753
– – 0.01% 1213
2018
Q4 		$654K Hold
753
– – 0.01% 1208
2018
Q3 		$779K Hold
753
– – 0.01% 1261
2018
Q2 		$692K Buy
753
+151
+25% +$162K 0.01% 1210
2018
Q1 		$587K Buy
602
+123
+26% +$112K 0.01% 1278
2017
Q4 		$217K Buy
+479
New +$177K ﹤0.01% 1882

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MetLife Investment Management's ATRA Position: Q4 2023 in Review

MetLife Investment Management sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 1,989 shares — an estimated $73.6K sold.

MetLife Investment Management first reported a position in ATRA in Q4 2017 and held it in 24 quarters. The position peaked at $779K in Q3 2018. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • MetLife Investment Management reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • MetLife Investment Management sold 1,989 Atara Biotherapeutics shares in Q4 2023, an estimated $73.6K.
  • MetLife Investment Management first reported a position in Atara Biotherapeutics in Q4 2017 and held it in 24 quarters.
  • MetLife Investment Management's Atara Biotherapeutics position peaked at $779K in Q3 2018.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.